Retour sur lavenir.net
   ENERGYVISION 14.500 € (+1,26 %)     IBA 16.900 € (-2,87 %)     TITAN S.A. 52.100 € (+3,17 %)     QRF 10.800 € (+0,47 %)     WERELDHAVE BELGIUM 52.600 € (+0,77 %)     VASTNED 30.150 € (+0,84 %)     WDP 22.160 € (+1,93 %)     PROXIMUS 6.530 € (-0,08 %)     UMICORE 22.640 € (+3,66 %)     KBC ANCORA 79.100 € (+3,53 %)     SOFINA 216.800 € (+2,26 %)     ARGENX SE 783.600 € (+1,03 %)     CIE BOIS SAUVAGE 310.000 € (+1,97 %)     ONWARD MEDICAL 2.625 € (-0,94 %)     FAGRON 24.750 € (+1,43 %)     GIMV 45.400 € (+2,37 %)     JENSEN-GROUP 84.400 € (+0,72 %)     MONTEA 67.000 € (+1,98 %)     HOME INVEST BE. 19.860 € (-0,30 %)     NYRSTAR 0.064 € (-8,31 %)     ONTEX GROUP 2.465 € (0,00 %)     AGFA-GEVAERT 0.423 € (+0,12 %)     RETAIL ESTATES 70.800 € (-0,14 %)     ASCENCIO 52.500 € (+2,74 %)     VIOHALCO 19.080 € (-1,75 %)     SOLVAC NOM(RETAIL) 76.000 € (+1,33 %)     TINC 11.860 € (+0,85 %)     MELEXIS 80.600 € (-0,68 %)     ACKERMANS V.HAAREN 280.000 € (+3,86 %)     LOTUS BAKERIES 11 700.000 € (-0,68 %)     CAMPINE 229.000 € (+0,44 %)     IMMOBEL 20.800 € (-0,95 %)     AB INBEV 71.280 € (+0,28 %)     D'IETEREN GROUP 169.500 € (+2,54 %)     VGP 81.800 € (+3,28 %)     AZELIS GROUP 10.430 € (+1,46 %)     CMB.TECH 13.320 € (+0,60 %)     EKOPAK 4.050 € (-1,22 %)     TESSENDERLO 20.350 € (+2,36 %)     CENERGY 24.100 € (-0,66 %)     BANQUP GROUP 1.545 € (+1,98 %)     BPOST 1.700 € (+1,31 %)     TUBIZE-FIN 241.800 € (+2,37 %)     RECTICEL 10.700 € (+2,10 %)     AEDIFICA 70.800 € (+1,80 %)     GBL 80.400 € (+1,20 %)     NYXOAH 1.406 € (-2,36 %)     SOLVAY 26.800 € (+1,98 %)     HYBRID SOFTWARE GR 4.060 € (+1,00 %)     SHURGARD 24.050 € (+2,78 %)     EVS 30.000 € (-0,17 %)     CARE PROPERTY INV. 12.380 € (-0,32 %)     COFINIMMO 83.100 € (+1,65 %)     BARCO 8.565 € (+1,24 %)     ECONOCOM GROUP 1.540 € (-1,91 %)     WHAT'S COOKING GP 146.000 € (0,00 %)     KBC 114.600 € (+3,38 %)     AGEAS 66.600 € (+1,14 %)     BREDERODE 103.000 € (+1,78 %)     XIOR 26.650 € (+1,14 %)  
   CALIBRE 0.000 € (-25,00 %)     AKZO NOBEL 57.780 € (+2,05 %)     STMICROELECTRONICS 67.750 € (+4,47 %)     SAINT GOBAIN 75.760 € (+3,38 %)     FUGRO 11.930 € (+0,85 %)     VINCI 125.900 € (+2,07 %)     BNP PARIBAS ACT.A 96.690 € (+5,17 %)     TOTALENERGIES 76.380 € (-2,08 %)     EURAZEO 42.480 € (+1,34 %)     BILENDI 15.200 € (0,00 %)     PULLUP ENTERTAIN 9.690 € (+10,11 %)     AXA 40.860 € (+0,96 %)     KALRAY 11.120 € (+12,66 %)     SANOFI 76.590 € (+0,38 %)     WOLTERS KLUWER 61.100 € (+0,69 %)     SIRIUS MEDIA 1.150 € (-11,54 %)     SCOR SE 31.040 € (+0,32 %)     INPOST 15.320 € (+0,20 %)     SAFRAN 306.100 € (+3,66 %)     ARCELORMITTAL SA 60.600 € (+5,87 %)     CORBION 20.160 € (+1,66 %)     MEDINCELL 27.420 € (-1,01 %)     NEXITY 7.830 € (+1,82 %)     TONNER DRONES 0.031 € (-9,73 %)     V LANSCHOT KEMPEN 68.500 € (+3,24 %)     SCHNEIDER ELECTRIC 265.300 € (+0,38 %)     AEGON 7.294 € (+2,76 %)     EUTELSAT COMMUNIC. 2.937 € (+0,14 %)     ASML HOLDING 1 629.600 € (+3,40 %)     ASM INTERNATIONAL 1 015.000 € (+4,25 %)     LUMIBIRD 24.000 € (+2,13 %)     MAISONS DU MONDE 0.437 € (+4,05 %)     HAFFNER ENERGY 0.276 € (+11,76 %)     AVANTIUM 7.800 € (+5,69 %)     ENGIE 27.510 € (+0,36 %)     CATANA GROUP 2.245 € (0,00 %)     PLUXEE 11.150 € (+1,73 %)     EXAIL TECHNOLOGIES 100.600 € (-16,17 %)     KAUFMAN ET BROAD 24.250 € (+0,83 %)     GENFIT 9.260 € (+4,99 %)     BE SEMICONDUCTOR 317.000 € (+2,96 %)     FORVIA 9.846 € (+4,57 %)     S.E.B. 55.050 € (+3,48 %)     EIFFAGE 126.500 € (+1,98 %)     ADYEN 828.400 € (+5,50 %)     LVMH 510.600 € (+3,53 %)     REWORLD MEDIA 1.700 € (-0,23 %)     CAPGEMINI 96.720 € (+1,32 %)     ABN AMRO BANK N.V. 34.670 € (+3,18 %)     VALEO 14.530 € (+1,82 %)     ALFEN 14.610 € (+1,25 %)     CRCAM BRIE PIC2CCI 37.600 € (+1,38 %)     SOCIETE GENERALE 73.400 € (+6,15 %)     ING GROEP N.V. 25.960 € (+3,55 %)     AIR FRANCE -KLM 11.855 € (+8,36 %)     STELLANTIS NV 5.900 € (+1,88 %)     L'OREAL 390.250 € (+1,81 %)     UMG 17.760 € (+0,14 %)     SES 8.250 € (+1,85 %)     GENOWAY 2.400 € (0,00 %)  
News Réglementées
31/01/2023 13:00

Avail Scientific Appoints Gerard Maynard as Chief Revenue Officer

TORONTO, ON / ACCESSWIRE / January 31, 2023 / MOBILE LADS, CORP., dba AVAIL SCIENTIFIC (OTC PINK:MOBO), is pleased to announce Gerard Maynard as Chief Revenue Officer ("CRO"). Following Avail's January 10th, 2023, Letter of Intent that outlined the terms for the acquisition of Relai Neuro at which Gerard Maynard is currently President. Gerard has over twenty years of experience building, and leading successful sales organizations, in digital marketing, healthcare, technology and IT management.

"I couldn't be more thrilled to join such an amazing organization as Avail Scientific. With Avail's new venture into neurological testing, data management as well as strategic partnerships in the mental health industry. This is a golden opportunity to drive revenues via Avail's neurological testing and analytics while building our strategic partnerships and long-term value. Avail is poised to have exponential growth over the next few years. I feel very fortunate to be a party of such a talented team" statement from Gerard Maynard Relai Neuro provides neurological testing and data management to rehab and mental health treatment centers in Florida. Avail Scientific's (MOBO) mandate is to support psychedelic medicine research and treatments through neurological testing, data analytics, and data management.

Website: https://www.relaineuro.com

Website: https://www.availscientific.com/

About Avail Scientific

Avail Scientific is working to facilitate a medical and social revolution of the current pharmacological therapies for addiction and the underlying causes by providing evidence-based diagnostic and data acquisition programs. These substances can be used as both treatment for addiction and as preventative therapy by addressing the health challenges underlying substance abuse.

We are building a platform to both educate and equip healthcare professionals with the data to use these therapeutic tools efficiently. Our objective is to treat this medical condition and prove out rehabilitation and preventative therapy programs with our partners in healthcare communities, both local and globally.

Avail Scientific is positioned to become a global leader in eliminating the needless suffering that surrounds addiction and mental health issues by providing effective data and patient monitoring to validate their efficacy.

Contact:

Dr. James Thompson
info@availscientific.com

Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements.

SOURCE: Mobile Lads, Corp.



View source version on accesswire.com:
https://www.accesswire.com/737297/Avail-Scientific-Appoints-Gerard-Maynard-as-Chief-Revenue-Officer

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière